Equities

Elutia Inc

ELUT:NAQ

Elutia Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.00
  • Today's Change0.14 / 3.63%
  • Shares traded8.53k
  • 1 Year change+142.42%
  • Beta0.7416
Data delayed at least 15 minutes, as of Sep 19 2024 17:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.

  • Revenue in USD (TTM)24.99m
  • Net income in USD-70.10m
  • Incorporated2015
  • Employees54.00
  • Location
    Elutia Inc12510 PROSPERITY DRIVE, SUITE 370SILVER SPRING 20904United StatesUSA
  • Phone+1 (240) 247-1143
  • Fax+1 (510) 307-9896
  • Websitehttps://elutia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
I-Mab ADR-100.00bn-100.00bn88.16m220.00--0.3751----------2.91-----------35.51---41.43-------509.54----0.00--111.86-13.6544.45---5.95--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.22m35.00391.37348.44--35.380.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
CASI Pharmaceuticals Inc23.10m-27.21m90.59m176.00--10.04--3.92-2.03-2.031.720.67310.35770.89172.39131,250.00-41.56-34.75-62.38-46.9156.8155.98-116.17-153.722.36--0.6718---21.41--34.27--14.65--
Rockwell Medical Inc94.37m-4.77m121.87m237.00--5.31--1.29-0.169-0.1693.210.75732.0713.9711.61398,194.10-10.48-46.29-16.25-65.3813.444.66-5.06-36.511.60-1.840.3144--14.845.6954.82--76.21--
Assertio Holdings Inc132.19m-345.11m123.94m53.00--0.9378--0.9376-4.11-4.111.441.390.38621.273.242,494,076.00-100.82-21.51-134.56-32.0572.1288.68-261.08-62.101.51--0.2266---2.67-13.38-402.80---28.25--
LifeVantage Corp200.16m2.94m126.54m217.0045.114.8819.410.63220.22480.224815.512.083.172.6687.77922,414.804.659.956.9515.5579.3081.451.473.081.01--0.0026.95-6.20-2.4015.63-16.94-2.18--
OptiNose Inc75.06m-40.91m128.16m132.00------1.71-0.3479-0.34790.6195-0.28630.63090.79093.50568,621.20-34.39-48.25-199.84-98.9589.9286.96-54.50-131.663.59-0.85371.52---6.9358.6452.58---27.96--
Elutia Inc24.99m-70.10m131.47m54.00------5.26-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Hongchang International Co Ltd4.65m-292.22k140.08m8.00--3.57--30.13-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Eton Pharmaceuticals Inc31.38m-6.69m152.69m30.00--11.30--4.87-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Biostem Technologies Inc131.44m7.87m158.96m67.0029.178.7819.661.210.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Lifecore Biomedical Inc128.26m9.33m160.67m524.0035.0914.058.831.250.14820.23183.831.760.50552.144.26244,774.803.68-5.914.35-8.3332.6331.017.27-19.161.060.23730.6923--24.20-25.46114.5334.47-16.72--
ASP Isotopes Inc2.30m-27.05m177.39m76.00--12.59--77.27-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Data as of Sep 19 2024. Currency figures normalised to Elutia Inc's reporting currency: US Dollar USD

Institutional shareholders

28.19%Per cent of shares held by top holders
HolderShares% Held
Nantahala Capital Management LLCas of 30 Jun 20241.80m6.04%
AIGH Capital Management LLCas of 30 Jun 20241.70m5.71%
SilverArc Capital Management LLCas of 30 Jun 20241.60m5.39%
Birchview Capital LPas of 30 Jun 20241.55m5.22%
Perkins Capital Management, Inc.as of 30 Jun 2024780.10k2.62%
The Vanguard Group, Inc.as of 30 Jun 2024485.51k1.63%
Kennedy Capital Management LLCas of 30 Jun 2024200.00k0.67%
Geode Capital Management LLCas of 30 Jun 2024125.36k0.42%
Alyeska Investment Group LPas of 30 Jun 202491.98k0.31%
Renaissance Technologies LLCas of 30 Jun 202453.62k0.18%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.